Metabolic / GLP-1U.S. Food & Drug Administration·2026
FDA proposes excluding semaglutide, tirzepatide & liraglutide from the 503B bulks list
The FDA's official press announcement formally proposing that semaglutide, tirzepatide and liraglutide be EXCLUDED from the 503B bulks list — the legal pathway that has allowed outsourcing facilities to compound these GLP-1s in bulk. If finalized, 503B facilities would no longer be permitted to mass-compound these molecules, ending the 'compounded GLP-1' era that emerged during the brand-name shortage.
STAT reports on the proposed federal rule that would functionally shut down large-scale compounding of GLP-1 weight-loss drugs. The piece walks through the regulatory mechanics, the political pressure from Novo Nordisk and Eli Lilly, and the patient-access fallout — millions of Americans currently rely on compounded versions priced a fraction of brand-name Wegovy and Zepbound.
Medscape's clinical breakdown of the FDA proposal targeting 503B outsourcing facilities. Coverage focuses on what the rule means for prescribers — including patients currently stabilized on compounded semaglutide or tirzepatide who may face supply disruption, sudden cost spikes, or forced switches back to brand-name products.
Becker's reports on the FDA's move to restrict 503B outsourcing facilities from compounding the leading GLP-1 molecules. The article frames the decision as the agency closing the door that opened during the official shortage period and details the implications for hospital pharmacies, telehealth platforms, and weight-loss clinics.
FDA moves to permanently close the door on compounded GLP-1s
Pharmacy Times details the FDA's proposal to permanently bar 503B outsourcing facilities from compounding semaglutide, tirzepatide and liraglutide. Once finalized, the rule would end large-scale compounding of these GLP-1s regardless of future shortages — a structural shift in access driven by safety, quality, and intellectual-property pressures.
GLP-1/GIP/PPAR quintuple agonist enters the obesity and diabetes race
C&EN profiles a next-generation incretin candidate stacking GLP-1, GIP, glucagon and PPAR activity into a single molecule, framed against retatrutide's triple-agonist results that already pushed mean weight loss past 24% at 48 weeks. The piece argues the quintuple-agonist class could outperform current GLP-1/GIP duals on both fat mass and lipid handling, while raising open questions about lean-mass loss, GI tolerability and long-term cardiovascular safety.
Metabolic / GLP-1New England Journal of Medicine·2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — NEJM Phase 2
48-week phase 2 trial in 338 adults with obesity. Retatrutide produced placebo-adjusted weight loss up to ~22.1% at the 12 mg dose, with dose-dependent improvements in waist circumference, blood pressure and lipids. GI adverse events were the dominant tolerability signal and were largely mitigated by slow titration.
Retatrutide in adults with type 2 diabetes — Phase 2 randomized trial
36-week study showing retatrutide reduced HbA1c by up to 2.16% and body weight by up to 16.94% in T2D patients, outperforming dulaglutide on both endpoints. Authors highlight the unique role of glucagon-receptor agonism in driving energy expenditure alongside appetite suppression.
Metabolic / GLP-1New England Journal of Medicine·2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Pivotal 72-week trial in 2,539 adults without diabetes. Tirzepatide produced mean weight reductions of 15–20.9% across doses vs 3.1% on placebo. Established the GLP-1/GIP dual-agonist class as a new benchmark for pharmacologic weight management.
Metabolic / GLP-1New England Journal of Medicine·2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
68-week phase 3 trial: semaglutide 2.4 mg weekly produced 14.9% mean weight loss vs 2.4% placebo, with broad cardiometabolic improvements. The data set the regulatory foundation for semaglutide's obesity indication and reframed clinical expectations for incretin therapy.
Cognitive / NootropicBulletin of Experimental Biology and Medicine·2008
Anxiolytic activity of the synthetic heptapeptide Selank
Preclinical work characterizing Selank's anxiolytic profile via modulation of GABA-ergic and serotonergic systems, with effects comparable to benzodiazepines in animal models but without sedation or dependence liability.
Cognitive / NootropicZh Nevrol Psikhiatr Im S.S. Korsakova·2008
Selank in generalized anxiety disorder and neurasthenia
Russian clinical study comparing intranasal Selank to medazepam in GAD patients. Selank showed comparable anxiolytic efficacy with an additional pro-cognitive effect and no withdrawal phenomena, supporting its profile as a non-sedating anxiolytic.
Semax, an analogue of ACTH(4–10), regulates BDNF and trkB expression
Demonstrates that Semax rapidly upregulates BDNF and its receptor trkB in the rat hippocampus — a leading mechanistic explanation for its reported nootropic and neuroprotective effects.
Cognitive / NootropicZh Nevrol Psikhiatr Im S.S. Korsakova·2011
Semax in acute ischemic stroke: a multicenter clinical study
Multicenter study reporting improved neurological recovery scores in ischemic stroke patients receiving intranasal Semax adjunctively within the first hours of stroke onset, attributed to neurotrophic and antioxidant effects.
Skin / HairOxidative Medicine and Cellular Longevity·2015
GHK-Cu peptide in skin remodeling, wound healing and anti-aging
Comprehensive review of GHK-Cu's pleiotropic effects: stimulating collagen, glycosaminoglycan and decorin synthesis, modulating gene expression linked to DNA repair, and accelerating wound closure. Frames GHK-Cu as a model 'signal peptide' for regenerative cosmeceuticals.
Bioinformatic analysis showing GHK modulates expression of ~31% of human genes toward a 'younger' transcriptomic signature, with downstream effects on tissue repair, anti-inflammatory pathways and cancer-suppressor activity.
Healing / RecoveryJournal of Orthopaedic Research·2011
BPC 157 accelerates tendon-to-bone healing and ligament repair
Rat model showing BPC-157 dramatically improves biomechanical strength of healing tendons and ligaments versus controls, via outgrowth of tendon fibroblasts and angiogenic effects.
Stable gastric pentadecapeptide BPC 157: cytoprotection and the gut-brain axis
Reviews BPC-157's cytoprotective effects across GI mucosa, vascular endothelium and the CNS, with emphasis on NO-system modulation and rescue of dopaminergic and serotonergic dysfunction in animal models.
Thymosin β4 promotes cardiac repair after myocardial infarction
Landmark Nature paper showing systemic Thymosin β4 (the parent of TB-500) reactivates epicardial progenitors and improves cardiac function after MI in mice — foundational evidence for its regenerative claims.
Growth HormoneEuropean Journal of Endocrinology·1998
Ipamorelin, the first selective growth hormone secretagogue
Original characterization of ipamorelin as a pentapeptide GH secretagogue with potent, selective GH release and minimal effect on cortisol or prolactin — establishing the safety profile that drives its modern use.
Growth HormoneJournal of Clinical Endocrinology & Metabolism·2006
Long-acting GHRH analog CJC-1295: pharmacokinetics and GH/IGF-1 effects
Phase 1 study showing single doses of CJC-1295 sustain elevated GH and IGF-1 for 1–2 weeks via albumin binding, supporting its use as a long-acting GHRH analog.
Growth HormoneNew England Journal of Medicine·2010
Tesamorelin reduces visceral adipose tissue in HIV-associated lipodystrophy
Phase 3 trial demonstrating tesamorelin produces a ~15% reduction in visceral adipose tissue with concurrent triglyceride improvements — the FDA-approval basis and a useful reference for visceral-fat targeting.
Epitalon (Epithalon) increases melatonin secretion and lifespan in animal models
Reports that the synthetic tetrapeptide Epitalon restores pineal melatonin rhythm in aged animals and extends mean lifespan, the central data point underlying longevity-focused use.
Bremelanotide (PT-141) for hypoactive sexual desire disorder
Phase 3 RECONNECT trial data supporting bremelanotide for HSDD in premenopausal women — a melanocortin-4 receptor agonist acting centrally rather than vasodilator-mediated.
ImmuneAnnals of the New York Academy of Sciences·2019
Thymosin α1 in immune modulation and infection
Reviews Thymosin α1's role in T-cell maturation, NK activity and clinical use in viral hepatitis, sepsis and oncology adjunctive care — the immunomodulatory rationale frequently cited in modern protocols.
KPV (Lys-Pro-Val), the C-terminal fragment of α-MSH, reduced colonic inflammation in murine colitis models via NF-κB suppression — supporting interest in oral/mucosal anti-inflammatory peptide therapy.
MOTS-c: a mitochondrial-derived peptide regulating metabolic homeostasis
Identifies MOTS-c as a mitochondrially encoded peptide that improves insulin sensitivity, prevents diet-induced obesity in mice and links mitochondrial signaling to systemic metabolism.
LongevityJournal of the American Society of Nephrology·2014
SS-31 (elamipretide) targets cardiolipin to restore mitochondrial function
Demonstrates SS-31's selective binding to cardiolipin on the inner mitochondrial membrane, preserving cristae structure and ATP production in models of ischemia-reperfusion injury.
Cardiotropic effects of Hexarelin independent of GH release
Shows hexarelin exerts direct cardioprotective effects via CD36 receptors in cardiac tissue, distinct from its GH-secretagogue activity — relevant to recovery and cardiovascular research applications.
Melanotan II: melanocortin agonism, pigmentation and sexual function
Reviews the pharmacology of MT-II as a non-selective melanocortin agonist, its skin-darkening mechanism via MC1R and erectogenic activity through MC4R, alongside known off-target risks.
Evidence that GHK-Cu enlarges hair follicle size and prolongs anagen phase in cultured human follicles, positioning copper peptides as adjuncts to standard androgenetic alopecia therapy.
